TCB-2 (original) (raw)
TCB-2 is a hallucinogen discovered in 2006 by Thomas McLean working in the lab of David Nichols at Purdue University. It is a conformationally-restricted derivative of the phenethylamine 2C-B, also a hallucinogen, and acts as a potent agonist for the 5-HT2A and 5-HT2C receptors with a Ki of 0.26 nM at the human 5-HT2A receptor. In drug-substitution experiments in rats, TCB-2 was found to be of similar potency to both LSD and Bromo-DragonFLY, ranking it among the most potent phenethylamine hallucinogens yet discovered. This high potency and selectivity has made TCB-2 useful for distinguishing 5-HT2A mediated responses from those produced by other similar receptors. TCB-2 has similar but not identical effects in animals to related phenethylamine hallucinogens such as DOI, and has been used f
| Property | Value |
|---|---|
| dbo:abstract | TCB-2 is a hallucinogen discovered in 2006 by Thomas McLean working in the lab of David Nichols at Purdue University. It is a conformationally-restricted derivative of the phenethylamine 2C-B, also a hallucinogen, and acts as a potent agonist for the 5-HT2A and 5-HT2C receptors with a Ki of 0.26 nM at the human 5-HT2A receptor. In drug-substitution experiments in rats, TCB-2 was found to be of similar potency to both LSD and Bromo-DragonFLY, ranking it among the most potent phenethylamine hallucinogens yet discovered. This high potency and selectivity has made TCB-2 useful for distinguishing 5-HT2A mediated responses from those produced by other similar receptors. TCB-2 has similar but not identical effects in animals to related phenethylamine hallucinogens such as DOI, and has been used for studying how the function of the 5-HT2A receptor differs from that of other serotonin receptors in a number of animal models, such as studies of cocaine addiction and neuropathic pain. (en) |
| dbo:casNumber | 912342-36-0 (hydrobromide) 912440-88-1 |
| dbo:chEMBL | 379637 |
| dbo:fdaUniiCode | 8U6Z2MP6H7 |
| dbo:pubchem | 16086382 |
| dbo:thumbnail | wiki-commons:Special:FilePath/TCB-2.png?width=300 |
| dbo:wikiPageID | 17254397 (xsd:integer) |
| dbo:wikiPageLength | 5343 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1112333056 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Potency_(pharmacology) dbr:Purdue_University dbr:David_E._Nichols dbr:Β-Methyl-2C-B dbc:Bromoarenes dbc:Phenol_ethers dbc:Psychedelic_phenethylamines dbr:S33005 dbr:Neuropathic_pain dbr:Conformational_isomerism dbr:2,5-Dimethoxy-4-iodoamphetamine dbr:Bromo-DragonFLY dbr:Dissociation_constant dbr:2CB-Ind dbr:2CBCB-NBOMe dbr:Agonist dbr:2C-B dbr:5-HT2A_receptor dbr:5-HT2C_receptor dbc:5-HT2A_agonists dbc:5-HT2C_agonists dbc:Benzocyclobutenes dbr:Receptor_(biochemistry) dbr:Hallucinogen dbr:Ivabradine dbr:Hydrobromide dbr:Jimscaline dbr:LSD dbr:Serotonin dbr:Substituted_phenethylamine dbr:Chemical_derivative dbr:Cocaine_addiction |
| dbp:atcPrefix | none (en) |
| dbp:br | 1 (xsd:integer) |
| dbp:c | 11 (xsd:integer) |
| dbp:casNumber | 912440 (xsd:integer) |
| dbp:casSupplemental | 912342 (xsd:integer) |
| dbp:chembl | 379637 (xsd:integer) |
| dbp:chemspiderid | 17245036 (xsd:integer) |
| dbp:h | 14 (xsd:integer) |
| dbp:iupacName | [-3-Bromo-2,5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine (en) |
| dbp:legalStatus | In General Unscheduled (en) |
| dbp:n | 1 (xsd:integer) |
| dbp:o | 2 (xsd:integer) |
| dbp:pubchem | 16086382 (xsd:integer) |
| dbp:routesOfAdministration | Oral (en) |
| dbp:smiles | COc1cccc2c1CC2CN (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | MPBCKKVERDTCEL-LURJTMIESA-N (en) |
| dbp:unii | 8 (xsd:integer) |
| dbp:verifiedrevid | 448096412 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Hallucinogens dbt:Phenethylamines dbt:Reflist dbt:Serotonergics dbt:Short_description dbt:Cascite dbt:Drugbankcite dbt:Fdacite |
| dcterms:subject | dbc:Bromoarenes dbc:Phenol_ethers dbc:Psychedelic_phenethylamines dbc:5-HT2A_agonists dbc:5-HT2C_agonists dbc:Benzocyclobutenes |
| gold:hypernym | dbr:Hallucinogen |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Abstraction100002137 yago:Element114840755 yago:Matter100020827 yago:Part113809207 yago:PhysicalEntity100001930 yago:Quintessence114847103 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:WikicatPhenolEthers |
| rdfs:comment | TCB-2 is a hallucinogen discovered in 2006 by Thomas McLean working in the lab of David Nichols at Purdue University. It is a conformationally-restricted derivative of the phenethylamine 2C-B, also a hallucinogen, and acts as a potent agonist for the 5-HT2A and 5-HT2C receptors with a Ki of 0.26 nM at the human 5-HT2A receptor. In drug-substitution experiments in rats, TCB-2 was found to be of similar potency to both LSD and Bromo-DragonFLY, ranking it among the most potent phenethylamine hallucinogens yet discovered. This high potency and selectivity has made TCB-2 useful for distinguishing 5-HT2A mediated responses from those produced by other similar receptors. TCB-2 has similar but not identical effects in animals to related phenethylamine hallucinogens such as DOI, and has been used f (en) |
| rdfs:label | TCB-2 (en) |
| owl:sameAs | freebase:TCB-2 yago-res:TCB-2 wikidata:TCB-2 dbpedia-sh:TCB-2 dbpedia-sr:TCB-2 https://global.dbpedia.org/id/4vf54 |
| prov:wasDerivedFrom | wikipedia-en:TCB-2?oldid=1112333056&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/TCB-2.png |
| foaf:isPrimaryTopicOf | wikipedia-en:TCB-2 |
| is dbo:wikiPageDisambiguates of | dbr:TCB |
| is dbo:wikiPageRedirects of | dbr:C11H14BrNO2 dbr:2C-BCB |
| is dbo:wikiPageWikiLink of | dbr:David_E._Nichols dbr:Β-Methyl-2C-B dbr:TCB dbr:2,5-Dimethoxy-4-iodoamphetamine dbr:C11H14BrNO2 dbr:2CB-Ind dbr:2CBCB-NBOMe dbr:5-HT2A_receptor dbr:Jimscaline dbr:TNF_inhibitor dbr:2C-BCB |
| is foaf:primaryTopic of | wikipedia-en:TCB-2 |
